Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer

Kelun-Biotech (6990.HK) is initiating clinical studies combining its novel CLDN18.2-directed antibody-drug conjugate (ADC) SKB315 with its PD-L1 monoclonal antibody tagitanlimab for first-line treatment of CLDN-positive gastric/gastroesophageal junction cancer (GC/GEJC), building on existing monotherapy studies and tagitanlimab's prior approval for nasopharyngeal carcinoma and Breakthrough Therapy Designation for non-small cell lung cancer; the combination aims to generate synergistic effects and improve survival benefits by addressing tumor heterogeneity.

Analysis

Kelun-Biotech (6990.HK) is advancing its oncology pipeline by initiating clinical studies for a combination therapy involving its novel CLDN18.2-directed antibody-drug conjugate (ADC), SKB315, and its PD-L1 monoclonal antibody, tagitanlimab. This combination is targeted for the first-line treatment of CLDN-positive gastric/gastroesophageal junction cancer (GC/GEJC), leveraging SKB315's proprietary humanized CLDN18.2 mAb and differentiated payload-linker design. This strategic development builds upon SKB315's ongoing monotherapy studies in CLDN-expressing tumors such as GC/GEJC and pancreatic ductal adenocarcinoma. Furthermore, it aligns with the clinical validation of tagitanlimab, which has NMPA marketing authorization for first-line nasopharyngeal carcinoma (NPC) and, in a separate combination, received Breakthrough Therapy Designation for first-line non-small cell lung cancer (NSCLC). The company anticipates that the distinct mechanisms of action of SKB315 and tagitanlimab will generate synergistic effects, potentially overcoming tumor heterogeneity and leading to improved survival benefits for patients. This initiative underscores Kelun-Biotech's focus on developing innovative treatments for major disease areas, particularly solid tumors, to address unmet medical needs.

Key Decisions for Investors

• Investors should closely monitor upcoming clinical trial data for the SKB315 and tagitanlimab combination, as positive results could significantly enhance the value of Kelun-Biotech's oncology pipeline.
• The progression of SKB315, both as a monotherapy and in combination, represents a key potential catalyst, particularly given the "strongly positive" sentiment and optimistic tone associated with this development in the promising ADC and immunotherapy synergy space.
• Given tagitanlimab's prior regulatory successes, the initiation of this combination study could de-risk the development pathway to some extent, although the inherent risks of clinical trials in oncology necessitate careful evaluation of future data releases.